Lilly Beats Q3 Revenue Estimates by About $2 Billion and Lifts Full-Year Guidance
- Lilly reported third-quarter revenue of $24.4 billion, up 39%, roughly $2 billion above Wall Street estimates, led by Mounjaro and Zepbound.
- Full-year revenue guidance rose by about $5.5 billion at the midpoint, to $91 to $92 billion.
- The quarter included about $900 million of non-recurring help, mainly $410 million of Jardiance milestones and favorable rebate adjustments.
💡 Points Based on public reports
Even stripped of the one-offs, the beat is large, and it widens the gap with Novo, which this week also lost a court bid to stop Lilly's ads. The guidance raise implies no supply or pricing brake yet. Retatrutide's head-to-head diabetes win adds a next leg, so the debate shifts from whether Lilly can grow to how much share it can take.